Monte Rosa Therapeutics Reports Positive Phase 1 Trial Data for Cardiovascular Disease Treatment

Monte Rosa Therapeutics announced positive data from a phase 1 study of MRT-8102, a molecular glue degrader being developed for inflammatory conditions in patients at elevated risk of cardiovascular disease.